Compare KBSX & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KBSX | PSTV |
|---|---|---|
| Founded | 1976 | 1996 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.0M | 61.1M |
| IPO Year | N/A | N/A |
| Metric | KBSX | PSTV |
|---|---|---|
| Price | $1.38 | $0.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 3.6K | ★ 4.3M |
| Earning Date | 02-11-2026 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $44,890,395.00 | $5,258,000.00 |
| Revenue This Year | N/A | $1.73 |
| Revenue Next Year | N/A | $12.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 30.46 | N/A |
| 52 Week Low | $1.26 | $0.16 |
| 52 Week High | $15.48 | $2.31 |
| Indicator | KBSX | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 40.79 | 49.76 |
| Support Level | $1.37 | $0.50 |
| Resistance Level | $1.60 | $0.58 |
| Average True Range (ATR) | 0.02 | 0.04 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 51.51 |
FST Corp is a renowned manufacturer and innovator in the golf industry with a growing portfolio of creative golf products, including acclaimed golf club shafts and other equipment. The Company has engaged in the research, development, manufacturing, and sales of golf club shafts. The Company currently produces and sells golf club shafts under the Company's own high performance KBS golf club shaft brand, and serves as an original equipment manufacturer (OEM) and original design manufacturer (ODM) for other world-renowned golf equipment brands, golf equipment OEMs, and golf equipment distributors that provide consumers with customized golf club services.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).